Biography and Research Information
OverviewAI-generated summary
Mika Taylor's research at the University of Arkansas for Medical Sciences focuses on developing novel immunotherapies for cancer. Recent publications investigate the repurposing of the live attenuated trivalent MMR vaccine as a cost-effective immunotherapy for cancer. Additionally, Taylor's work explores enhancing immune responses and survival rates in hepatocellular carcinoma through the use of the oncolytic Jurona virus in conjunction with immune checkpoint blockade. This research includes a comprehensive proteogenomic analysis to assess the in vivo safety and immunoactivity of the oncolytic Jurona virus in hepatocellular carcinoma models. Taylor collaborates with researchers including Steven R. Post, Martin J. Cannon, Camila Simões, and Bolni Marius Nagalo, all from the University of Arkansas for Medical Sciences, with whom they have co-authored four publications.
Metrics
- h-index: 2
- Publications: 4
- Citations: 12
Selected Publications
-
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)
-
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)
Collaboration Network
Top Collaborators
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
Similar Researchers
Based on overlapping research topics